• Phio Pharmaceuticals Corp (NASDAQ: PHIO) said it expects to file an IND in the U.S. in the first half of 2023 for a Phase 1b clinical trial of its INTASYL compound, PH-762. 
• Phio is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology is designed to make immune cells more effective in killing tumor cells. 
• PH-762 has been shown to reduce the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. When administered intratumorally in preclinical models, PH-762 primes an anti-tumor immune response and inhibits tumor growth.
• Related: Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells.
• Phio is currently conducting a Phase 1b clinical trial of PH-762 for advanced melanoma.
• Phio expects to commence a US Phase 1b clinical trial early in the 2nd half of 2023. The initial US trial is expected to focus on cutaneous squamous cell carcinoma and other selected cutaneous malignancies.
• Price Action: PHIO shares are up 4.08% at $0.39 during the premarket session on the last check Thursday.

See more from Benzinga

• ORIC Pharmaceuticals Shares Move Higher After Equity Infusion, Clinical Collaboration From Pfizer
• Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
• Here's How Much Marjorie Taylor Greene Has Lost On Her Trump SPAC Investment - Digital World Acq (NASDAQ:

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.